We serve Chemical Name:[1-(2-benzoyloxynaphthalen-1-yl)naphthalen-2-yl] benzoate CAS:291772-40-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[1-(2-benzoyloxynaphthalen-1-yl)naphthalen-2-yl] benzoate](https://a.dearchem.com/CAS2/291772-40-2.png)
Chemical Name:[1-(2-benzoyloxynaphthalen-1-yl)naphthalen-2-yl] benzoate
CAS.NO:291772-40-2
Synonyms:d272;MFCD00183872
Molecular Formula:C34H22O4
Molecular Weight:494.53600
HS Code:
Physical and Chemical Properties:
Melting point:163-166ºC
Boiling point:729.2ºC at 760 mmHg
Density:1.268g/cm3
Index of Refraction:1.694
PSA:52.60000
Exact Mass:494.15200
LogP:8.09840
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like d272 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00183872 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00183872 Use and application,MFCD00183872 technical grade,usp/ep/jp grade.
Related News: Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries. 3,9-Diazabicyclo[4.2.1]nonane, 9-(3-pyridinyl)-, (1S,6R)- manufacturers A possible reason for this is that developments within the biocatalysis field have fast outpaced existing knowhow, leaving some pharmaceutical companies unaware of the vast range of options available. Keeping abreast of both current and emerging developments within the field of biocatalytic processing is key when it comes to maintaining a competitive edge. rel-(1R,5R)-5-methyl-3-vinylcyclohex-2-en-1-ol suppliers The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 1,3-bis(4-(4-nitrophenoxy)phenyl)adamantane vendor & factory EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. ,EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time.
